



Lymphatic blood filling in CLEC-2-deficient mouse
models
Haining, Elizabeth; Lowe, Kate; Wichaiyo, Surasak; Kataru, Raghu P; Nagy, Zoltan;
Kavanagh, Dean; Lax, Sian; Di, Ying; Nieswandt, Bernhard; Ho-Tin-Noé, Benoît; Mehrara,




Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Haining, E, Lowe, K, Wichaiyo, S, Kataru, RP, Nagy, Z, Kavanagh, D, Lax, S, Di, Y, Nieswandt, B, Ho-Tin-Noé,
B, Mehrara, BJ, Senis, Y, Rayes, J & Watson, S 2020, 'Lymphatic blood filling in CLEC-2-deficient mouse
models', Platelets. https://doi.org/10.1080/09537104.2020.1734784
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iplt20
Platelets
ISSN: 0953-7104 (Print) 1369-1635 (Online) Journal homepage: https://www.tandfonline.com/loi/iplt20
Lymphatic blood filling in CLEC-2-deficient mouse
models
Elizabeth J Haining, Kate L Lowe, Surasak Wichaiyo, Raghu P Kataru, Zoltan
Nagy, Dean Pj Kavanagh, Sian Lax, Ying Di, Bernhard Nieswandt, Benoît Ho-
Tin-Noé, Babak J Mehrara, Yotis A Senis, Julie Rayes & Steve P Watson
To cite this article: Elizabeth J Haining, Kate L Lowe, Surasak Wichaiyo, Raghu P Kataru, Zoltan
Nagy, Dean Pj Kavanagh, Sian Lax, Ying Di, Bernhard Nieswandt, Benoît Ho-Tin-Noé, Babak J
Mehrara, Yotis A Senis, Julie Rayes & Steve P Watson (2020): Lymphatic blood filling in CLEC-2-
deficient mouse models, Platelets, DOI: 10.1080/09537104.2020.1734784
To link to this article:  https://doi.org/10.1080/09537104.2020.1734784
© 2020 The Author(s). Published with
license by Taylor & Francis Group, LLC
View supplementary material 
Published online: 04 Mar 2020. Submit your article to this journal 
Article views: 385 View related articles 
View Crossmark data
Lymphatic blood filling in CLEC-2-deficient mouse models
Elizabeth J Haining 1, Kate L Lowe1, Surasak Wichaiyo1,2, Raghu P Kataru3, Zoltan Nagy 1*, Dean Pj Kavanagh1,
Sian Lax1, Ying Di1, Bernhard Nieswandt 4, Benoît Ho-Tin-Noé5, Babak J Mehrara3, Yotis A Senis 1
#
,
Julie Rayes 1,6, & Steve P Watson 1,6
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK, 2Department of
Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand, 3Division of Plastic and Reconstructive Surgery, Department of Surgery,
Memorial Sloan Kettering Cancer Center, New York, NY, USA, 4Rudolf Virchow Center for Experimental Biomedicine and Institute of Experimental
Biomedicine, University of Würzburg and University Hospital of Würzburg, Würzburg, Germany, 5Institut National de la Santé et de la Recherche
Médicale, UMR_S1148, Université Paris Diderot, Sorbonne Paris Cité, Hôpital Bichat, Paris, France, and 6Centre of Membrane Proteins and Receptors
(COMPARE), Universities of Birmingham and Nottingham, The Midlands, UK
Abstract
C-type lectin-like receptor 2 (CLEC-2) is considered as a potential drug target in settings of
wound healing, inflammation, and infection. A potential barrier to this is evidence that CLEC-2
and its ligand podoplanin play a critical role in preventing lymphatic vessel blood filling in
mice throughout life. In this study, this aspect of CLEC-2/podoplanin function is investigated in
more detail using new and established mouse models of CLEC-2 and podoplanin deficiency,
and models of acute and chronic vascular remodeling. We report that CLEC-2 expression on
platelets is not required to maintain a barrier between the blood and lymphatic systems in
unchallenged mice, post-development. However, under certain conditions of chronic vascular
remodeling, such as during tumorigenesis, deficiency in CLEC-2 can lead to lymphatic vessel
blood filling. These data provide a new understanding of the function of CLEC-2 in adult mice
and confirm the essential nature of CLEC-2-driven platelet activation in vascular developmental
programs. This work expands our understanding of how lymphatic blood filling is prevented by
CLEC-2-dependent platelet function and provides a context for the development of safe
targeting strategies for CLEC-2 and podoplanin.
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Introduction
C-type lectin-like receptor 2 (CLEC-2) is a hemITAM containing
receptor (defined by a single YxxL sequence) that is highly expressed
on platelets and regulates many of the non-classical functions of these
cells, including in inflammation and infection [1]. Podoplanin, the
primary ligand for most of the known CLEC-2 functions, is a mucin-
type protein with a short intracellular tail. It has a broad expression
profile including on lymphatic endothelial cells [2], alveolar epithelial
type I cells [3,4], stromal cells and fibroblasts [5–7], inflammatory
leukocytes [4,8,9] and specialized tissue structures such as in kidney
podocytes [10] and on choroid plexuses in the brain [11,12]. CLEC-2
(as a consequence of its expression on platelets) and podoplanin have
been proposed as novel targets in a wide range of disorders including
sepsis, wound repair, infection, and cancer metastasis [4,8,13–17]. If
these novel therapy approaches are to become a reality, it is vital that
the functions of CLEC-2-mediated platelet activation, and the ligand
podoplanin, are fully understood in healthy adult individuals as well as
in these disorders.
Genetic studies in mice have shown that activation of platelets via
the interaction of podoplanin and CLEC-2 is essential during devel-
opment to prevent deleterious blood filling of the lymphatic system
[18–21]. This maintenance in separation between the two developing
vasculatures is understood to occur by at least two distinct mechan-
isms, dependent on anatomical location. At the connection between
the thoracic duct and the junction of the subclavian and internal
jugular veins, platelet-rich thrombi have been found in embryonic
and neonatal mice [22]. Evidence suggests that CLEC-2-mediated
platelet activation at this site, triggered by podoplanin expression on
the lymphovenous valves, drives this thrombus formation. The addi-
tional physical barrier, provided by the thrombi, supports the devel-
oping junctions and valves in preventing excessive blood backflow
into the thoracic duct [22], although it remains unclear why this does
not also prevent forward lymphatic flow [22]. In embryonic mesen-
tery, red blood cell leakage from the developing venous vasculature
has been identified as a transient, natural occurrence [23]. The devel-
oping lymphatic vessels are thought to aid in the clearance of this
leakage, as red blood cells can be found in, and associated with,
wildtype lymphatic vessels [23]. CLEC-2-mediated activation of
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platelets by lymphatic endothelial cells and podoplanin-expressing
stromal cells is thought to reduce the severity of blood leakage from
the developing veins and may also contribute to the organization of
lymphatic endothelial cell clusters, thus preventing the developing
lymphatics from becoming overwhelmed and consequently blood-
filled and malformed [23].
The importance of the contribution of platelets and podoplanin-
expressing cells to these processes is, on the one hand, clear; mutation
or loss ofCLEC-2 or its downstream signalingmolecules, Syk, Slp-76,
and PLCγ2 constitutively, or conditionally in the hematopoietic line-
age, results in perinatal lethality and a striking blood-filled, edematous,
lymphatic phenotype [19,24–29]. Furthermore, immunodepletion of
CLEC-2 [30,31] during the neonatal period [22] or generation of adult
chimericmice reconstitutedwithCLEC-2-deficient bonemarrowafter
lethal irradiation [24,25,32] also leads to the progressive blood filling
of the lymphatic vasculatures, with the latter leading to a dramatic,
lethal destruction of lymphatic function. The constitutive loss of
podoplanin expression and targeted loss of podoplanin during the
neonatal period also lead to blood filling of the lymphatics
[20,21,33]. These observations have led to the conclusion that
CLEC-2-mediated platelet function is important throughout life to
prevent the deleterious breakdown of the separation between the
blood and lymphatic systems, with particular importance placed on
the lymphovenous junction at the top of the thoracic duct [34].
The conclusion that CLEC-2 mediated platelet activation is
required throughout life to prevent lymphatic blood filling is
however challenged by a number of observations. Mice that are
conditionally deficient in platelet expressed CLEC-2 survive with
expected Mendelian frequency into adulthood, in contrast to con-
stitutively CLEC-2-deficient animals, which die within 24 h of
birth [24]. This is despite the clear presence of blood in the
lymphatic system, albeit more mild at the embryonic stage than
in constitutively deficient mice. Furthermore, drugs, such as ibru-
tinib or fostamatinab, which inhibit kinases (Btk and Tec, or Syk,
respectively), that play a key role in the CLEC-2 hemITAM
signaling cascade, are routinely used in the long-term treatment
of hematological malignancy or refractory thrombocytopenia
[35,36]. Patients receiving these drugs are not reported to exhibit
evidence of blood-filled lymphatics.
In the present study, we have further investigated the
hypothesis that interaction between platelet-expressed CLEC-
2 and podoplanin is required post-development to prevent
lymphatic blood filling by using existing and new mouse
models of CLEC-2 deficiency, and novel models of lymphan-
giogenesis. These models include approaches that allow
assessment of CLEC-2 deficiency in adult mice without con-
founding influence from developmental defects and a newly
developed conditional model generated by GpIba-driven Cre
expression to delete CLEC-2 in platelets [37]. In addition, we
have addressed the role of podoplanin signaling in this process
using a new mouse model that lacks the cytoplasmic tail of
podoplanin and has normal levels of podoplanin expression
during development but not in adult mice. Using these models,
we show that the interaction between platelet expressed
CLEC-2 and podoplanin is not required to protect the lympha-
tic system from blood filling in unchallenged mice once devel-
opment is complete. However, under certain conditions of
chronic vascular remodeling, such as after lethal irradiation
and tumorigenesis, adult deficiency in CLEC-2 can lead to
lymphatic vessel blood filling. These data provide a new
understanding of the function of CLEC-2 in adult mice, con-
firm the essential nature of CLEC-2 driven platelet activation
in vascular developmental programs, and indicate that signal-
ing of podoplanin is not important in this process. This work
provides a context for the development of safe targeting stra-
tegies for podoplanin and CLEC-2.
Results
Loss of the Podoplanin Cytoplasmic Tail Triggers Podoplanin
Shedding in Adult Mice, but Not Lymphatic Vessel Blood
Filling
Mice constitutively expressing a truncated form of podoplanin which
lacks the cytoplasmic tail (Pdpn K164STOP) were generated by tar-
geted insertion of three stop codons immediately after the podoplanin
transmembrane domain coding region using CRISPR/Cas9-mediated
gene editing (Supplementary Figure 1ai–iii). PdpnK164STOP embryos
at E12.5 - E14.5 were viable and podoplanin expression was compar-
able to wildtype embryos, as detected by immunohistochemistry
(Figure 1ai–ii). Evidence of blood filling in developing dermal lym-
phatics and hemorrhage was observed in ~50% of embryos. The
remaining Pdpn K164STOP embryos appeared no different to wildtype
littermate embryos, in which these abnormalities were not observed
(Figure 1bi–ii). As described for a similar strain of podoplanin knock-
in mice [38], Pdpn K164STOP mice were born and survived with the
expected Mendelian ratios and were indistinguishable in appearance
from littermate controls (Supplementary Figure 1b). Unlike in
embryos, western blotting for podoplanin expression in adult lung
tissue revealed reduced podoplanin expression, which was confirmed
by immunohistochemistry using two different antibodies against
podoplanin, and by flow cytometry of lung tissue cell subsets
(Figure 1ci–ii) and Supplementary Figure 1ci–ii). This reduction in
expression was also observed, and in some cases was more severe, in
kidney, liver, heart, spleen, and skin as shown by immunochemistry
(Figure 1di–ii) and, in the case of kidney, was also confirmed by
western blotting (Supplementary Figure 1d). Western blotting and
ELISA detected soluble podoplanin in the plasma of all Pdpn
K164STOP animals tested but not all wildtype animals indicating that
the primary cause for the loss of podoplanin expression is shedding of
the protein from the cell surface (Figure 1ei–ii). Despite the severe
reduction in podoplanin expression, there were no signs of lymphatic
vessel blood filling in adult Pdpn K164STOP mice, although bleeding
in lymph nodes could be observed (Supplementary Figure 1e).
Together these data indicated that after normal levels of podo-
planin expression during development, the loss of the cytoplasmic
tail (and therefore signaling capabilities) led to constitutive shedding
of the protein from the cell surface. This deficiency did not appear to
cause lymphatic blood filling in adult mice.
Loss of CLEC-2 in Adult Mice Does Not Lead to a Lymphatic
Blood Filling Phenotype
As the marked widespread reduction of podoplanin in adult
mice did not cause a lymphatic blood filling defect, the
effects of CLEC-2 deletion in adult mice were investigated
using the previously published tamoxifen-inducible CLEC-
2-deficient strain [4,32]. In order to compare and quantify
lymphatic blood filling phenotypes between mouse strains,
a scoring system was developed based on macroscopic images
of lymphatic vessels and lymph nodes from various anatomi-
cal locations (see Methods and Supplementary Figure 2).
When CLEC-2 was deleted in inducible knockout mice after
weaning, there was no evidence of lymphatic blood filling
after 8 weeks of continuous tamoxifen exposure (Figure 2ai,
ii). Loss of CLEC-2 from platelets after tamoxifen treatment
in adult mice was confirmed by flow cytometry and capillary-
based immunoassay (Figure 2bi–ii and Supplementary
Figure 3) and no change in platelet counts was observed
over the course of tamoxifen exposure (Figure 2(c)).
Although there was no evidence of lymphatic blood filling,
blood leakage in lymph nodes was observed after tamoxifen
treatment in inducible CLEC-2-deficient mice (Figure 2di–ii).
This observation was not altered by the method of tamoxifen
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delivery to the mice (Supplemental Figure 4) or when target-
ing CLEC-2 by tamoxifen treatment was supplemented with
repeat injections of the anti-CLEC-2 immunodepletion anti-
body INU1 (Supplementary Figure 5). Intravital imaging of
the intestinal arcades with an arterial infusion of fluorescent
dextran confirmed that there were no microscopic connections
between the circulatory and lymphatic systems in tamoxifen-
inducible CLEC-2-deficient mice (Supplementary Figure 6).
Tamoxifen is known to have anti–inflammatory effects [32,39] and
this may have influenced the results. Therefore, to validate the model
Figure 1. Downregulation of podoplanin in adult mice does not cause lymphatic blood filling.(A) Representative images of embryonic lung tissue from Pdpn
K164STOP and wildtype (littermate) animals. Sections stained for podoplanin (brown) and hematoxylin (blue). Yellow arrows indicate podoplanin positive
structures within the lung tissue in animals from both genotypes, n = 3. Scale bar Ai = 50 µm. (Bi) Representative images and (Bii) quantification of the two
types of gross phenotypes seen in Pdpn K164STOP E14.5 embryos. Type 1 = indistinguishable from wildtype (13/25), Type 2 = blood-filled dermal lymphatic
vessels and hemorrhage (12/25). (Ci) Western blotting for podoplanin in adult Pdpn K164STOP lung tissue revealed a decrease in podoplanin expression in
comparison towildtype lung (Cii) Representative images of podoplanin stained adult lung tissue from PdpnK164STOP andwildtype animals which also show the
decrease in podoplanin expression detected by western blotting. Sections stained for podoplanin (brown) and hematoxylin (blue), n = 3 Scale bar = 50 µm. (Di)
Representative images of tissue sections from different organs of Pdpn K164STOP and wildtype animals show the widespread loss of podoplanin expression
across many different adult tissues in Pdpn K164STOP mice. Sections stained for podoplanin (brown) and hematoxylin (blue), n = 3 Scale bar = 50 µm. (Ei)
Western blotting for soluble podoplanin in adult Pdpn K164STOP plasma revealed an increase of podoplanin in comparison to wildtype plasma. (Eii) ELISA for
soluble podoplanin in adult PdpnK164STOP plasma revealed a significant increase in podoplanin detection in comparison towildtype plasma. n = 6. Significance
determined by Mann–Whitney U test. ** = p < .01
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Figure 2. Loss of CLEC-2 in adult mice does not lead to a lymphatic blood filling phenotype.(Ai) Lymphatic vessel score. Gross images of various anatomical
sites from wildtype (CLEC-2fl/fl) and inducible CLEC-2-deficient (CLEC-2fl/fl CreERT2) mice were scored and no evidence of lymphatic blood filling could be
identified 8 weeks after weaning onto tamoxifen containing diet. Bars represent median, error bars represent the interquartile range and dots represent individual
animals. The black dotted line indicates the maximum score possible. Significance assessed by Mann–Whitney U test. (Aii) Images representative of n = 3–7.
Abbreviations: SE= sub-epigastric collector (indicated by yellowarrow); scale bar=250 µm, TD= thoracic duct (indicated by yellowarrow); scale bar= 500 µm,
Arc = intestinal arcade; scale bar = 1mm. (Bi) Peripheral blood samples were taken at the point of weaning and then 2 and 8 weeks after tamoxifen exposure and
CLEC-2 surface levels assessed by flow cytometry. Dotted red line represents the average mean fluorescent intensity (MFI) of isotype control antibody. (Bii)
Capillary-based immunoassay for CLEC-2 in platelet lysates from wildtype and inducible CLEC-2-deficient mice after 8 weeks of tamoxifen diet confirmed the
loss of CLEC-2 expression in platelets after tamoxifen exposure. Image representative of n = 4. (C) Platelet counts of wildtype and inducible CLEC-2-deficient
mice in acid-citrate-dextrose anticoagulatedwhole bloodweremeasured at the point of weaning and then 2 and 8weeks after tamoxifen exposure by an automated
hematology analyzer. No alteration in platelet counts was identified over the course of exposure for either genotype (n = 6–12). (Di) Inducible CLEC-2-deficient
mice developed bleeding in lymph nodes after tamoxifen exposure. Bars representmedian, error bars represent the interquartile range and dots represent individual
animals. The black dotted line indicates the maximum score possible. Significance assessed by Mann–Whitney U test. (Dii) Images representative of n = 3–7.
Abbreviations: ILN = inguinal lymph node; scale bar = 1 mm, MLN = mesenteric lymph nodes; scale bar = 1 mm.
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Figure 3. Targeting CLEC-2 expression in embryos and neonates results in lymphatic blood filling.(Ai) CLEC-2fl/fl female mice were time-mated with
CLEC-2fl/fl CreERT2 males and then treated with 1.5 mg 4-hydroxytamoxifen (4-OHT) by gavage for 4 consecutive days beginning at 8.5 d.p.c.
Embryos were then taken for analysis at E14.5 (Aii) CLEC-2fl/fl female mice were time-mated with CLEC-2fl/fl CreERT2 males and resultant litters were
treated with 50 µg 4-OHT by intragastric injection for 3 consecutive days beginning at P0. Treated litters were then taken for analysis 14 days after the
last 4-OHT injection. (B) E14.5 embryos from 4-OHT treated females were imaged and inducible CLEC-2-deficient (CLEC-2fl/fl CreERT2) embryos
clearly displayed blood filling of the developing dermal lymphatics (yellow arrowhead). Presented gross images are representative of four inducible
CLEC-2-deficient embryos from three litters. (Ci) Lymphatic vessel scoring of tamoxifen-treated, inducible CLEC-2-deficient mouse pups and
tamoxifen-treated wildtype littermate controls revealed blood-filled lymphatics in 4/4 CLEC-2 deficient animals and 0/3 wildtype littermates. (Cii)
Representative images of CLEC-2 deficient and wildtype littermate lymphatic vessels used for scoring. (Di) Lymph node scoring revealed blood-filled
lymph nodes in 4/4 CLEC-2 deficient animals and 0/3 wildtype littermates. (Dii) Representative images of CLEC-2 deficient and wildtype littermate
lymph nodes used for scoring. For both lymphatic vessel and lymph node scoring, gross images were blinded before being scored by two independent
researchers as described in the methods. Bars represent median, error bars represent the interquartile range and dots represent individual animals. The
black dotted line indicates the maximum score possible. Significance assessed by Mann–Whitney U test. (Cii) SE = sub-epigastric collector (indicated
by yellow arrow); scale bar = 250 µm, TD = thoracic duct (indicated by yellow arrow); scale bar = 500 µm, Arc = intestinal arcade; scale bar = 1 mm.
(Dii) ILN = inguinal lymph node; scale bar = 1 mm, MLN = mesenteric lymph nodes; scale bar = 1 mm.
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Figure 4. Gp1ba-Cre conditional CLEC-2 deficiency results in blood filling of the lymphatic vasculature.CLEC-2 expression levels in Gp1ba-Cre
CLEC-2-deficient platelets were assessed by flow cytometry in whole blood (Ai) and capillary-based immunoassay in platelet lysates (Aii left).
Complete loss of CLEC-2 from Gp1ba-Cre CLEC-2-deficient platelets was determined by both methods. This was also the case for Pf4-Cre CLEC-
2-deficient platelets analyzed in parallel by capillary-based immunoassay (Aii right). Dotted red line in Ai represents the average mean fluorescent
intensity (MFI) of isotype control antibody. Aii shows images representative of n = 4 for all mouse strains. (B) Platelet counts of Gp1ba-Cre transgenic
(Gp1ba-Cre+/KI) and Gp1ba-Cre CLEC-2-deficient mice were measured in acid-citrate-dextrose anticoagulated whole blood by an automated
hematology analyzer. A 14% reduction in circulating platelet count was found in Gp1ba-Cre CLEC-2-deficient mice (n = 8–12). Gross images of
various anatomical sites from wildtype (CLEC-2fl/fl) and conditional CLEC-2-deficient mice (aged between 8 and 12 weeks) were scored as described
in the methods to generate an assessment of blood filling of lymphatic vessels (Ci) and bleeding in lymph nodes (Di). Gp1ba-Cre CLEC-2-deficient
mice had a significantly lower lymphatic vessel score than Pf4-Cre CLEC-2-deficient mice but there was no difference in lymph node scores between
the strains. Gross images were blinded before being scored by two independent researchers. Bars represent median, error bars represent the
interquartile range and dots represent individual animals. The black dotted line indicates the maximum score possible. Significance assessed by
Kruskal–Wallis one-way analysis of variance and Dunn’s multiple comparison post hoc test. (Cii) Representative images of CLEC-2 deficient and
wildtype littermate lymphatic vessels used for scoring. Images representative of n = 12. Abbreviations: SE = sub-epigastric collector (indicated by
yellow arrow); scale bar = 250 µm, TD = thoracic duct (indicated by yellow arrow); scale bar = 500 µm, Arc = intestinal arcade; scale bar = 1 mm.
(Dii) Representative images of CLEC-2-deficient and wildtype littermate lymph nodes used for scoring. Images representative of n = 11.
Abbreviations: ILN = inguinal lymph node; scale bar = 1 mm, MLN = mesenteric lymph nodes; scale bar = 1 mm.
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and control for unanticipated effects of tamoxifen on lymphatic blood
filling, CLEC-2 was targeted in this strain during embryonic and
neonatal developmental stages (Figure 3ai–ii). Targeting CLEC-2 in
embryos (Figure 3b) and neonates (Figure 3ci–dii) caused lymphatic
blood filling to develop within days and weeks, respectively.
These results indicate CLEC-2 is not required to prevent lymphatic
blood filling in adult mice as indicated by the lack of phenotype in
adult Pdpn K164STOP mice.
Gp1ba-Cre Conditional CLEC-2 Deficiency Results in Blood
Filling of the Lymphatic Vasculature
As targeting of CLEC-2 and podoplanin in unchallenged adult
mice did not lead to signs of lymphatic blood filling, the contribu-
tion of platelets in preventing this process throughout life was
brought into question. Generation of platelet-specific conditional
knockout mice has relied on the Pf4-Cre mouse model [40], which
has been shown to also delete expression of target proteins outside
of the megakaryocyte lineage [37,41–43]. To isolate the contribu-
tion of platelets to the development of blood-filled lymphatics, the
newly developed Gp1ba-Cre-driven model (Gp1ba is only known
to be expressed in megakaryocytes) [37] was used to generate
a lineage-specific conditional CLEC-2-deficient mouse strain.
Gp1ba-Cre CLEC-2-deficient mice were born, and survived,
with Mendelian ratios and were indistinguishable in appearance
from littermate controls. Flow cytometry and capillary-based
immunoassay confirmed that platelets from these mice did not
express detectable levels of CLEC-2 (Figure 4ai–ii and
Supplementary Figure 7a). Aggregation studies confirmed that
platelets from these mice were functionally unresponsive to the
CLEC-2 agonist Rhodocytin (Supplementary Figure 7b). As seen
in Pf4-Cre CLEC-2-deficient mice [44,45], the new strain had
a small reduction in circulating platelet count in the order of 15%
(Figure 4b) which we have previously concluded is due to lym-
phatic blood filling [19,24]. Using the lymphatic vessel and
lymph node score previously described, Gp1ba-Cre CLEC-
2-deficient mice were found to have a less severe infiltration of
blood into the lymphatic system in comparison to Pf4-Cre CLEC-
2-deficient mice, although blood was clearly present relative to
wildtype controls (Figure 4ci,ii). In contrast, bleeding in lymph
nodes, which is due to increased permeability at high endothelial
venules [46], was similar between the two strains (Figure 4di,ii).
Figure 5. Genetic GPVI deficiency potentiates lymphatic blood filling in Gp1ba-Cre CLEC-2-deficient mice.Gross images were scored as described in
the methods to generate an assessment of blood filling of lymphatic vessels (Ai) and bleeding in lymph nodes (Bi) in GPVI knockout and Gp1ba-Cre
CLEC-2/GPVI double-deficient mice (aged between 8 and 20 weeks). Gp1ba-Cre CLEC-2/GPVI double-deficient mice had a significantly higher
score than Gp1ba-Cre CLEC-2-deficient mice for both lymphatic vessels and lymph nodes. GPVI-deficient mice showed no evidence of lymphatic
vessel blood filling but did show evidence of bleeding in lymph nodes. Gross images were blinded before being scored by two independent researchers.
Bars represent median, error bars represent the interquartile range and dots represent individual animals. The black dotted line indicates the median
score of Gp1ba-Cre CLEC-2-deficient mice. Stars indicate the statistical difference between Gp1ba-Cre CLEC-2 and CLEC-2/GPVI deficient mice,
which was assessed by Mann–Whitney U test. (Aii) Images representative of n = 12. Abbreviations: SE = sub-epigastric collector (indicated by yellow
arrow); scale bar = 250 µm, TD = thoracic duct (indicated by yellow arrow); scale bar = 500 µm, Arc = intestinal arcade; scale bar = 1 mm. (Bii)
Images representative of n = 12. Abbreviations: ILN = inguinal lymph node; scale bar = 1 mm, MLN = mesenteric lymph nodes; scale bar = 1 mm.
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The presence of blood in lymphatic vessels and lymph nodes
of Gp1ba-Cre CLEC-2-deficient mice both confirmed and pro-
vided further evidence that loss of CLEC-2 from platelets is a key
component of the mechanisms that lead to these defects.
Gp1ba-Cre CLEC-2/GPVI Double-Deficient Mice Show
Increased Lymphatic Blood Filling
A recent advance in the understanding of lymphatic blood filling
in embryonic CLEC-2-deficient strains came from the observa-
tion that developing lymphatic vessels in embryonic skin contain
red blood cells that have escaped from the developing venous
vasculature [23]. To explore the relationship between venous
integrity and lymphatic blood filling in embryogenesis and into
adulthood further, we assessed the lymphatic blood filling phe-
notype of Gp1ba-Cre CLEC-2-deficient mice on a GPVI-
deficient background. These two platelet receptors have been
shown to act in concert to prevent endothelial cell leakage at
sites of inflammation in the vasculature, a process termed inflam-
matory hemostasis [1].
Similar to Pf4-Cre CLEC-2/GPVI double-deficient mice [45],
Gp1ba-Cre CLEC-2/GPVI double-deficient mice are viable and
have increased infiltration of blood into lymphatic vessels relative
to Gp1ba-Cre CLEC-2-deficient mice; GPVI-deficient mice, in
contrast, have no evidence of lymphatic blood filling (Figure 5ai–
ii). Bleeding in lymph nodes, however, was comparable between
Gp1ba-Cre CLEC-2-deficient mice on both wildtype and GPVI-
deficient backgrounds (Figure 5bi–ii). An additional finding was
Figure 6. The lymphatic blood filling phenotype of platelet conditional CLEC-2-deficient mice does not progress after development.Gross images of
conditional CLEC-2-deficient mice of two age groups (1 month or younger but weaned, and 3 months or older) and were scored as described in the
methods to generate an assessment of blood filling of lymphatic vessels (A) and bleeding in lymph nodes (B). There was no statistical difference
between the age groups within a strain for the lymphatic vessel score; however, the lymph node score increased in the older age groups of Gp1ba-Cre
CLEC-2-deficient and Gp1ba-Cre CLEC-2/GPVI double-deficient mice (n = 8 for all strains). (C) GPVI-deficient mice also showed a significant
increase in lymph node score in mice aged 4 months or over when compared to those 1 month or younger, but weaned (n = 6). Bars represent median,
error bars represent the interquartile range and dots represent individual animals. The black dotted line indicates the maximum score possible.
Significance assessed by Mann–Whitney U test for each strain.
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evidence of minor bleeding in lymph nodes in GPVI-deficient mice
(Figure 5ai–ii).
These results demonstrate an increase in lymphatic blood fill-
ing in the combined absence of GPVI and platelet expressed
CLEC-2, which may be due to an increase in vessel leakage.
The Lymphatic Blood Filling Phenotype of Platelet
CLEC-2-deficient Mice Does Not Progress Post-development
To investigate the differences between the Pf4-Cre and Gp1ba-
Cre CLEC-2-deficient strains further, the severity of the lympha-
tic blood filling phenotypes was compared between mice of
different ages. The hypothesis behind this approach is that back-
filling of blood into the lymphatic system from the venous system
would be expected to increase over time. However, in all three
strains, there was no change in the respective severities of the
lymphatic blood filling phenotype between mice of different ages
(Figure 6a). This was in contrast to bleeding in lymph nodes,
which was significantly more severe in older Gp1ba-Cre CLEC-
2-deficient mice and CLEC-2/GPVI double-deficient strains
(Figure 6b). This was also the case in mice deficient in GPVI
(Figure 6c).
The absence of progressive lymphatic blood filling in all
CLEC-2-deficient strains tested provides further evidence that
CLEC-2 is not required throughout life in unchallenged mice to
prevent lymphatic blood filling.
Lymphangiogenesis Does Not Require Platelet CLEC-2 in
Adult Mice
During development, the blood and lymphatic networks form
through vasculogenesis, angiogenesis, intussusception, and vas-
cular remodeling [47–50]. To study the differential requirement
for CLEC-2 during and after development in more detail, these
processes were ectopically induced in adult CLEC-2-deficient
mice. To assess lymphangiogenesis independently from blood
vascular remodeling, a newly developed mouse model of lympha-
tic endothelial cell-specific induced PTEN deficiency (Flt-4
Figure 7. Induced lymphangiogenesis in adult mice does not require platelet expressed CLEC-2 to prevent blood filling.Flt-4 CreERT2 PTENfl/fl mice
were received three consecutive intraperitoneal injections of tamoxifen in corn oil, followed 2 days later by intraperitoneal injection of 2 µg/g INU1
IgG which was repeated 5 days later. Tissues were assessed 14 days after the first tamoxifen injection. (A) Platelet counts of induced Flt-4 CreERT2
PTENfl/fl mice were measured in heparin anticoagulated whole blood samples (taken before each INU1 IgG injection) by an automated hematology
analyzer. Bars represent mean, error bars represent standard deviation and dots represent individual animals. (B) Platelet CLEC-2 expression was
assessed by flow cytometry in heparinized whole blood samples taken before each INU1 IgG injection. Bars represent mean % CLEC-2 positive
platelets, error bars represent standard deviation and dots represent individual animals. (Ci) Surface coverage of initial lymphatic vessels was analyzed
using ImageJ in wholemount ear tissue stained with anti-Lyve1 antibody, Induced Flt-4 CreERT2 PTENfl/fl mice had an increase in surface area
coverage over noninduced animals however there was no difference in surface overage between INU1 treated and untreated induced animals as
determined by ANOVA. Bars represent mean, error bars represent standard deviation and dots represent individual animals. (Cii) Representative
images of wholemount ear skin from INU1 treated and untreated induced Flt-4 CreERT2 PTENfl/fl mice.
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CreERT2 PTENfl/fl) was combined with the anti-CLEC-2 immu-
nodepletion antibody INU1 [30,31]. In this model, lymphangio-
genesis is initiated by tamoxifen-induced deletion of PTEN from
lymphatic endothelial cells causing an intrinsically driven, self-
limiting expansion of the lymphatic vascular network (Kataru
et al. manuscript under consideration). Two days after tamoxifen
induction, CLEC-2 depletion from platelets was initiated and then
maintained by injections of the CLEC-2-depleting antibody,
INU1, every 5 days. This treatment did not alter platelet count
(Figure 7a) but provided sustained depletion of CLEC-2
Figure 8. CLEC-2 deficiency during chronic, but not acute, dermal vascular remodeling can lead to localized lymphatic vessel blood filling.Pf4-CreCLEC-2
deficient mice and littermate wildtype controls were subjected to cutaneous reverse passive Arthus reaction (rpA) and skin biopsies were collected 4 h after
reaction initiation. In neither genotype could blood-filled lymphatic vessels be identified by gross or microscopic assessment. (Ai) Representative images of
rpA-challenged skin from Pf4-Cre CLEC-2 deficient mice and littermate wildtype controls. (Aii) Representative images of rpA-challenged skin sections
from Pf4-Cre CLEC-2 deficient mice and littermate wildtype controls stained for podoplanin (brown) and hematoxylin (blue). Lymphatic vessels indicated
by yellow arrows. Scale bar = 100 µm. Wildtype mice rendered thrombocytopenic by treatment of 2 µg/g of anti-GpIba rat anti-mouse monoclonal antibody
mixture (R300) 18 h before rpA initiation had red blood cells in lymphatic vessels upon microscopic inspection. (Bi) Representative images of non-inflamed
and inflamed areas of rpA-challenged skin sections from thrombocytopenic wildtype mice stained for podoplanin (brown) and hematoxylin (blue) and red
blood cells (yellow). Lymphatic vessels indicated by yellow arrows. Scale bar = 50 µm. n = 4. (Bii) Quantification of the presence of red blood cells in
podoplanin positive lymphatic vessels in rpA-challenged skin sections from thrombocytopenic wildtypemice. Pf4-CreCLEC-2 deficient mice and littermate
wildtype controls received an intradermal injection of B16F10 melanoma cells into back skin. After 12 days of tumor growth, skin was harvested. (C)
Representative images of melanoma-challenged skin from Pf4-CreCLEC-2 deficient mice and littermate wildtype controls and quantification of blood-filled
tumor-associated lymphatic vessels (yellow arrows) in Pf4-Cre CLEC-2 deficient mice. n = 10.
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expression from platelets (Figure 7b) after a transient thrombocy-
topenia which has been reported in wildtype mice upon injection
of INU1 [30]. Two weeks after induction, the surface coverage
and quality of the lymphatic network in ear skin were not different
between INU1 treated and sham-treated PTEN-deficient mice,
although both groups had expanded lymphatic network surface
coverage compared to non-induced controls (Figure 7ci–ii and
Supplementary Table 1). There was also no macroscopic evidence
of blood filling of the lymphatic network in INU1 treated mice
(data not shown).
This provides evidence that in adult mice, platelet expressed
CLEC-2 is not required during for isolated, intrinsically driven
lymphatic network expansion.
CLEC-2 Deficiency during Chronic, but Not Acute, Dermal
Vascular Remodeling Can Lead to Localized Lymphatic
Vessel Blood Filling
The clear contribution of platelet expressed CLEC-2 signal-
ing during development, but not during isolated lymphangio-
genesis, indicated that both blood and lymphatic vascular
remodeling may be required for blood filling of the dermal
lymphatics under certain conditions. Therefore, two challenge
models for both the blood and lymphatic vasculatures were
assessed in adult Pf4-Cre CLEC-2-deficient mice. The cuta-
neous reverse passive Arthus reaction (rpA) was selected as
an acute, localized inflammation model that elicits a vascular
response without inducing vessel growth or network remodel-
ing [51]; the melanoma tumor model was selected as
a chronic inducer of inflammation and vascular network
remodeling and growth [52,53]. In Pf4-Cre CLEC-2-deficient
animals, rpA-induced local skin inflammation did not lead to
macro or microscopic evidence of blood filling
dermal lymphatics adjacent to, or within, the site of inflam-
mation (Figure 8ai–ii). As blood leakage through the
endothelium is not seen in CLEC-2-deficient mice during
the rpA reaction [54], wildtype mice rendered severely
thrombocytopenic to induce leakage [54–56] were also
assessed for a more direct comparison to the observations
of vascular leakage during dermal vascular development. In
rpA-inflamed skin from thrombocytopenic wildtype (which
as expected showed extensive blood leakage into the tissue)
red blood cells could be found inside lymphatic vessels
(Figure 8b). This indicated that adult dermal lymphatic ves-
sels can also aid in the clearance of extravascular red blood
cells that have leaked into the tissue. However, in this acute
and localized model, there was no evidence of blood filling
of lymphatic vessels either in wildtype or CLEC-2-deficient
mice. In contrast, tumorigenesis induced by intradermal
injection of B16F10 melanoma cells was associated with
blood-filled lymphatics in approximately 33% of Pf4 CLEC-
2-deficient mice compared to wildtype mice (Figure 8c).
These results indicated that although in adult CLEC-2-defi-
cient mice lymphatic blood filling does not occur during the
expansion of lymphatic vessels in isolation, it can occur during
the chronic concomitant remodeling of the blood and lymphatic
vasculatures as seen in tumors.
Discussion
Previous studies of mouse models of CLEC-2 deficiency have led
to the conclusion that platelet expressed CLEC-2 is required
throughout life to prevent blood filling of the lymphatic system
by backflow through the thoracic duct-venous junction. The pre-
sent study shows that CLEC-2-driven platelet activation is
dispensable for the infiltration of blood into the lymphatic system
in unchallenged adult mice. In contrast, CLEC-2 is required for
the separation during development and vascular remodeling in
challenged adult mice.
Analysis of the Pdpn K164STOP mouse strain provided the first
indication that there may be a differential requirement between
developmental and adult stages for CLEC-2/podoplanin function
in maintaining vascular separation. This was due to the unex-
pected finding that truncation of podoplanin to remove the
9-amino acid intracellular tail causes a widespread loss of protein
expression in adult, but not embryonic, tissues without initiating
lymphatic blood filling. The presence of seemingly normal podo-
planin expression in embryonic tissue and the finding of soluble
podoplanin in the plasma of Pdpn K164STOP mice strongly indi-
cates shedding of the protein as a primary mechanism for this
loss. Podoplanin has been previously identified as a substrate for
both γ-secretase and metalloproteases [21,57,58]. The explanation
as to why podoplanin is shed in adult but not during embryogen-
esis is not known.
The lack of a lymphatic blood filling phenotype in Pdpn
K164STOP embryos and the apparently normal function of the
lymphatic network in mice of this strain indicates that the
cytoplasmic tail, and therefore the signaling of podoplanin,
does not play a role in this process. This result, together with
the similar phenotype of constitutive podoplanin- and CLEC-
2-knockout mouse models, suggests that the role of podopla-
nin in the prevention of blood-lymphatic mixing is due to its
role as a ligand for CLEC-2 rather than as a signaling
receptor.
This is despite the fact that engagement and clustering of
podoplanin by CLEC-2 and other ligands are thought to have
consequences for cell shape [5,59], motility [60] and cytoskeletal
organization [61,62].
The major finding of this work is the absence of lymphatic
blood filling in inducible CLEC-2-deficient adult mice.
Combined with the lack of phenotype progression in platelet
conditional CLEC-2-deficient mouse models, this indicates that
the origin of this phenotype lies in defects acquired during
development and not in a continual process. Hess et al. [22]
reported that anti-CLEC-2 antibody treatment of newborn mice
leads to lymphatic blood filling. We have confirmed this result
in newborn mice but not in adult mice and speculate that this
can be explained by the fact that the lymphatics are still
developing at the time of birth. It has been concluded from
bone marrow transplantation experiments [22,28] that only
a small number of wildtype platelets are required in this
mechanism. Immunoassay of platelet lysates confirmed that
CLEC-2 was efficiently lost from all platelets. However, as
an extra level of caution against any remaining CLEC-2
expression, immunodepletion of CLEC-2 by antibody injection
was used to supplement CLEC-2 targeting by tamoxifen treat-
ment of inducible mice. Again, there was no evidence of
lymphatic blood filling in unchallenged mice providing the
strongest evidence that CLEC-2 expression is not required to
prevent blood-lymphatic mixing throughout life. While the
present results demonstrate that platelets are not required to
prevent lymphatic-blood mixing in unchallenged mice living in
a largely sterile environment, they do not rule out a possible
role in mice living in the wild or in humans who are exposed
to a much larger titer and range of pathogens.
The finding that CLEC-2 does not play a continuous, basal role in
preventing lymphatic blood filling opens questions regarding the
mechanisms that control this process and where this occurs. As
thrombus formation has been shown to support the lymphovenous
junction during development, there may be differences in the struc-
ture and function of the thoracic duct–venous junction between adult
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and developing mice. Although it is known that other areas of the
lymphatic system undergo extensive remodeling during the neonatal
period (such as in the mesentery [63]), how and if this anatomical
structure matures is unknown. Application of advanced in vivo
imaging is required to interrogate this further, and indeed may
provide information of relevance for procedures that may affect
thoracic duct maturation in humans, such as the pediatric Fontan
surgical procedure for univentricular hearts [64].
Although the loss of CLEC-2 post-development did not lead to
lymphatic blood filling, inducing chronic vascular remodeling in
platelet CLEC-2-deficient adult mice caused localized lymphatic
blood filling, additional to the underlying defect in these mice. An
important aspect of this observation is its comparison to the normality
of induced lymphangiogenesis in the absence of platelet expressed
CLEC-2.Unlike the latter which does not elicit blood vessel alteration,
solid tumor growth extensively remodels the surrounding blood and
lymphatic vasculatures and induces both de novo and angiogenic
growth of new vessels [53,65]. It appears then for lymphatic blood
filling to occur there is a requirement for a concomitant change to both
blood and lymphatic vasculatures as suggested during dermal vascu-
lature development [23] and in response to ionizing radiation exposure
[66–68]. On the face of it, this is logical as it is difficult to understand
how platelets and other blood components would encounter lymphatic
vessels to induce effects and filling if the blood vasculature is not
compromised in some aspect. However, this may not account for other
tissue-specific interactions or connections that may occur in tissues
other than the skin.
The use of the newly developed Gp1ba-Cre mouse has provided
evidence that the blood lymphatic mixing in embryos is due to loss
of CLEC-2 on platelets. The more mild nature of the phenotype
relative to constitutive or Pf4-Cre conditional mice could be due to
delayed expression of the Cre in this model [37,69]. Although in
adult mice all three models produce platelets that do not express
CLEC-2, this difference in Cre expression may be of importance
during primitive hematopoiesis. Alternatively, it could also be due to
the involvement of an additional CLEC-2 expressing cell type.
Further work dissecting the expression profile of CLEC-2 during
the early stages of primitive hematopoiesis and the interaction of
embryonic platelets with the various tissue-specific sources of lym-
phatic endothelium are required to better understand both the
mechanisms that underlie the role of CLEC-2 during development
and the differences between the constitutive and conditional mouse
models of CLEC-2 deficiency.
The mechanism of bleeding into lymph nodes is distinct from
that of lymphatic blood filling [38,46]. This is further corrobo-
rated in the present study by the demonstration of bleeding into
lymph nodes following the depletion of CLEC-2 in adult mice in
contrast to the absence of blood-filled lymphatics. Furthermore,
we also observed a previously unappreciated contribution of
GPVI in preventing bleeding into lymph nodes and demonstrated
that the severity of bleeding in this structure increases over time
in CLEC-2- and GPVI-deficient mouse models.
In conclusion, this work provides evidence that CLEC-2-driven
platelet function is not continually required to protect the lymphatic
vasculature from blood filling in unchallenged adult mice, although it
is required during chronic, concomitant remodeling of the adult blood
and lymphatic vasculatures. These insights open questions regarding
the mechanisms that maintain the discrete nature of blood and lym-
phatic vessels as they develop and remodel side-by-side.
Methods
Mice
Animals maintained at the Biomedical Services Unit, Birmingham
University, UK, were in individually ventilated cages under a 12-
h:12-h light/dark cycle at a constant temperature of 20°C with food
and water given ad libitum. All experiments were performed in
accordance with UK laws [Animal (Scientific Procedures) Act
1986] with approval of the local ethics committee and UK Home
Office approval under PPL P14D42F37. Clec1bfl/fl mice with either
Pf4-Cre or Rosa26-CreERT2 (CreERT2) have been described pre-
viously [5,14,24,32], as have PTENfl/fl mice with Flt-4 CreERT2
(Kataru et al. manuscript under consideration). To generate the
GpIba-Cre CLEC-2 deficient strain, Clec1bfl/fl female mice were
interbred withGpIba-Cre+/KImales to eventually produceClec1bfl/fl
GpIba-Cre+/KImice and Clec1bfl/fl littermate control mice. Animals
bred and maintained in the UKwere fed with FormulaLab Diet 5008
(Laboratory-Diet). When required, 3–4 week old Clec1bfl/fl
CreERT2 mice and their Clec1bfl/fl control littermates were fed for
up to 1 year with tamoxifen-supplemented diet TAM400 (Envigo).
Alternative tamoxifen delivery routes included 5 consecutive intra-
peritoneal injections of 2 mg tamoxifen in corn oil (to mice aged
6weeks and older), gavage of 1.5mg 4-hydroxytamoxifen in corn oil
(to pregnant females) and intragastric injection of 50 µg 4-hydro-
xytamoxifen in corn oil (to neonates aged P0 – P3).
Antibodies and Reagents
Anti-CLEC-2 rat anti-mouse monoclonal antibody (INU1, used
in vivo) and rat anti-mouse control monoclonal antibody have
been previously described [31]. Anti-CLEC-2 rat anti-mouse
monoclonal antibody (17D9, used for flow cytometry) and rat
anti-mouse control monoclonal antibody were from BioRad.
Sheep anti-CLEC-2 polyclonal antibody (DIY1, used for immu-
noassay) was generated in house. Anti-CD41 rat anti-mouse
monoclonal antibody (MWReg30, used for flow cytometry) was
from ThermoFischer Scientific and the anti-GAPDH rabbit mono-
clonal antibody (14C10, used for immunoassay) was from Cell
Signaling Technology. Anti-podoplanin antibody (8.1.1,
eBiosciences) and anti-podoplanin goat anti-mouse polyclonal
antibody (AF3244, R&D) were used for western blot, ELISA,
and immunohistochemistry. Dietary tamoxifen was delivered by
TAM400 (Envigo), tamoxifen, 4-hydroxytamoxifen, and corn oil
were from Sigma. Melanoma cell line.
Flow Cytometry
For analysis of platelet CLEC-2 surface expression whole blood,
diluted 1:500 in PBS, was incubated with FITC conjugated anti-
CLEC-2 rat anti-mouse monoclonal antibody, 17D9 or a FITC
conjugated isotype control antibody, and an APC conjugated anti-
CD41 rat anti-mouse monoclonal antibody (MWReg30, to iden-
tify platelets) for 15 min at room temperature. The mean fluor-
escent intensity of CD41 positive events was analyzed using a BD
Accuri™ (BD Biosciences).
Immunoblotting
CLEC-2 expression was analyzed using an automated capil-
lary-based immunoassay platform; Wes (ProteinSimple).
Briefly, 5 × 108 platelets/ml was lysed by the addition of
equal volume of ice-cold 2× lysis buffer, and lysates were
diluted to the required concentration with 0.1× sample buffer.
Lysates were prepared by the addition of a 5× master mix
containing 200 mM dithiothreitol (DTT), 5× sample buffer and
fluorescent standards (Standard Pack 1, PS-ST01-8) and boiled
for 5 min at 95°C according to the manufacturer’s instructions.
Samples, antibody diluent 2, primary and secondary antibo-
dies, luminol S-peroxide mix and wash buffer were displaced
into Wes 12–230 kDa prefilled microplates (pre-filled with
12 E. J. Haining et al. Platelets, Early Online: 1–16
separation matrix 2, stacking matrix 2, split running buffer 2
and matrix removal buffer, SM-W004). The microplate was
centrifuged for 5 min at 2500 rpm at room temperature. To
start the assays, the capillary cartridge was inserted into the
cartridge holder and the microplate placed on the plate holder.
To operate Wes and analyze the results, Compass Software for
Simple Western was used (version 3.1.7, ProteinSimple).
Separation time was set to 31 min, stacking loading time to
21 s, sample loading time to 9 s, primary antibodies were
incubated for 30 min and for detection the High Dynamic
Range (HDR) profile was used. For analysis of CLEC-2 sig-
nal, platelet lysates were first deglycosylated by Rapid
PNGase F (New England Biolabs) according to the manufac-
turer’s instructions. The optimized dilution for the custom-
made sheep anti-mouse CLEC-2 antibody was 1:40 and the
final lysate concentration was 0.2 mg/ml. The anti-GAPDH
antibody (14C10, Cell Signaling Technology) was used as
previously described [70].
Lymphatic Vessel and Lymph Node Scores
To allow comparison of lymph node bleeding, and lymphatic
vessel blood filling phenotypes between different CLEC-2-defi-
cient mouse stains, a manual scoring system was developed
based on gross images taken postmortem with a Nikon
SMZ800 stereomicroscope (1.5× objective, and 1–6.3× zoom)
fitted with a Nikon Digital Sight DS-Fi1 camera. Animals were
culled with an overdose of sodium pentobarbital delivered by
intraperitoneal injection and pinned down in the supine posi-
tion. A midline incision from the base of the tail to the jaw tip
was made in the skin, followed by further incisions along each
limb (just above the arms and just behind the legs). The skin
was peeled back and pinned down to present the underside of
the skin and lymph nodes, and the following anatomical areas
were imaged: inguinal lymph nodes, sub-epigastric lymphatic
collectors, axillary lymph nodes, and maxillary lymph nodes.
A midline incision was then made in the peritoneum and the
following anatomical areas were imaged: mesenteric lymph
nodes and arcades of the small intestine (duodenum, jejunum,
and ileum). Finally, the right side of the ribcage was removed
and the heart and lungs held to the left to allow visualization
and imaging of the thoracic duct. Blinded images of these
anatomical sites were scored by an independent researcher
based on the presence of blood in each structure, indicated
by red or brown discoloration, as follows: lymphatic vessels
(including sub-epigastric collectors, one score for left and right,
intestinal arcades, one score, and thoracic duct) 0–2, with 0
being indistinguishable from wildtype; lymph nodes (including,
inguinal, axillary, maxillary, and mesenteric, one score for each
site, left and right) 0–3, with 0 being indistinguishable from
wildtype. Full descriptors and example images of each score
can be found in Supplemental Figure 2. The scores from each
site were summed to provide one number used to describe the
bleeding in lymph nodes and lymphatic blood filling for each
animal.
Ear Tissue Wholemount Immunostain
Ear tissue was immunostained with anti-Lyve-1 goat anti-rabbit
polyclonal antibody and an Alexa594 conjugated anti-goat sec-
ondary as previously described [71]. Briefly, anterior and poster-
ior ear skin was separated and cleaned of connective tissue and
cartilage. The anterior tissue was pinned flat and fixed with 4%
paraformaldehyde for 1 h at room temperature. After fixation
tissue was permeabilized with PBS containing 1% Tween 20
(PBST) and blocked with PST containing 3% BSA and 5% goat
serum for 1 h before staining overnight with primary antibody
followed by 5 h at room temperature with secondary antibody.
Stained tissues were imaged with a confocal microscope (Leica
Microsystems) and the visualized lymphatic networks analyzed
using Fiji and AngioTool [72].
Cutaneous Reverse Passive Arthus Reaction
The cutaneous rpA was induced in the back skin of mice as
described previously [54,56]. Rabbit anti-BSA IgG was injected
intradermally in mouse back skin (60 µg in 20 µL saline, 2 spots/
mouse). This was immediately followed by intravenous injection
of BSA (50 µg/g mouse) in saline. Mice were euthanized after 4
h and skin biopsies at control and reaction sites harvested for
fixation and paraffin embedding. For experiments with thrombo-
cytopenia, 2 µg/g of anti-GpIba rat anti-mouse monoclonal anti-
body mixture (R300, Emfret Analytics) was injected via the tail
vein into mice 24 h before rabbit anti-BSA IgG injection.
Melanoma Tumor Model
Cell culture: Murine B16F10 melanoma cells (CRL-6475)
were purchased from ATCC. Cells were cultured at 37°C in
a humidified atmosphere of 5% CO2, high glucose (4.5 g/L)
DMEM supplemented with 10% fetal bovine serum and 1%
glutamine and were used by passage 10 for implantation into
syngeneic recipient mice. Tumor cell implantation: 100 μL of
B16F10 melanoma cells at 1.0 × 107/mL in Dulbecco’s
phosphate-buffered saline (PBS) were injected subcuta-
neously into the back of 6- to 8-week-old Pf4-Cre Clec1bfl/
fl female mice.
Statistics
Results are presented as mean ± standard deviation apart from
lymphatic vessel and lymph node scores which are presented as
median ± interquartile range. Student’s t-test was the statistical
analysis used apart from the following data sets: lymphatic
vessel and lymph node scores (comparison of three groups or
more) Kruskal–Wallis one-way analysis of variance and Dunn’s
multiple comparison post hoc test, lymphatic vessel and lymph
node scores (comparison of two groups) Mann–Whitney U test.
p < .05 were classed as significant.
Study Approval
All animal studies were performed in accordance with UK laws
[Animal (Scientific Procedures) Act 1986] with approval of the
local ethics committee and UK Home Office approval under PPL
P14D42F37.
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